Next Generation of CardioQ

Deltex Medical Group PLC
23 April 2008


                            Deltex Medical Group plc

             Next generation CardioQ-ODM(TM) monitor released for sale

23 April 2008 - Deltex Medical Group plc ('Deltex Medical' or 'the Company'),
the UK's leading haemodynamic monitoring company, today announces the release of
the CardioQ-ODM(TM), the next generation of its market leading oesophageal
Doppler monitor (ODM).


The CardioQ-ODM offers a number of enhancements over the current model, the
CardioQTM

   • Enhanced patient management and event recording
   • Upgraded compatibility with hospital networking systems
   • Expanded data-download options
   • Faster data processing capability
   • More memory
   • Improved user interfaces
   • Storage of multiple individual users' preferences
   • Simplified default display, emphasising the measured parameters unique
    to ODM

The CardioQ-ODM is being made available for sale initially in the UK and in the
Company's key markets in Continental Europe, Latin America and the Far East. The
Company is preparing its application for clearance of the CardioQ-ODM by the US
regulatory authorities and expects to release it into the US market in the
latter part of 2008. To support its continuing expansion in the USA in the
meantime, the Company intends to use its remaining stocks of CardioQ monitors,
supplemented as required by CardioQ units recovered from existing customers
under CardioQ-ODM upgrade schemes.

Deltex Medical's Chief Executive, Andy Hill commented:

'The launch of the CardioQ-ODM monitor further extends our first-mover advantage
in the fast-growing market for technology that allows real-time management of
patients' circulating blood volumes before, during and after surgery and in
critical care.

'Our decision to call the new monitor the CardioQ-ODM reflects the perception in
global medical markets that Deltex Medical is THE oesophageal Doppler monitoring
company. This is timely, as it is becoming increasingly clear that oesophageal
Doppler guided fluid management allows doctors to intervene earlier, more safely
and more effectively than any fluid management protocols that use other
technologies which do not directly measure blood flow.'

For further information, please contact:-

Deltex Medical Group plc                 01243 774 837
Nigel Keen, Chairman                     [e-mail]
Andy Hill, Chief Executive               [e-mail]
Ewan Phillips, Finance Director          [e-mail]

Gavin Anderson & Company                 0207 554 1400
Deborah Walter                           [e-mail]
Robert Speed                             [e-mail]

Charles Stanley Securities               020 7149 6000
(Nominated Adviser)
Philip Davies                            [e-mail]
Russell Cook                             [e-mail]


Notes for Editors

Deltex Medical manufactures and markets the CardioQ-ODM(TM) monitor, which uses
disposable ultra-sound probes inserted into the oesophagus to determine the
amount of blood being pumped around the body - 'circulating blood volume'.
Reduced circulating blood volume is known as hypovolaemia, which leads to
insufficient oxygen being delivered to the organs. This causes medical
complications including peripheral and major organ failure which can lead to
death. Hypovolaemia, which is akin to severe dehydration, affects virtually
every patient having surgery because of the combined effects of pre-operative
starvation, the impact of the anaesthetic agents and trauma from the surgery
itself. Using fluids and drugs, guided by the CardioQ-ODM, to optimise the
amount of circulating blood significantly reduces post-operative complications
allowing patients to make a faster, more complete recovery and return home
earlier.

The CardioQ-ODM incorporates the Company's proprietary software and a small
diameter, easy-to-use, minimally invasive, disposable oesophageal probe that is
used for transmitting and receiving an ultra-sound signal. By using this
technology, the CardioQ-ODM provides clinicians with the ability to
haemodynamically optimise critically ill patients and those undergoing routine
moderate to major surgery through the controlled administration of fluid and
drugs. Haemodynamic optimisation has been scientifically proven to improve the
speed and quality of patient recovery and reduce hospital stay.

There are already over 1,500 CardioQ-ODMs currently in use in hospitals
worldwide and distribution arrangements are in place in over 30 countries. In
addition, there are currently more than 100 clinical publications on the use of
the CardioQ-ODM which have repeatedly:-

   •Validated the results of the Monitor against known standards for
    measuring cardiac output, demonstrating that the technology works

   •Proved that the CardioQ-ODM works in a wide range of surgical procedures

   •Demonstrated that the Company's technology provides significant health
    and economic benefits by helping to reduce post-operative complications and
    length of hospital stays by an average of 30 to 40 per cent for a wide range
    of patients.

The SupraQ(TM) is an entirely non-invasive device which uses an ultrasound probe
held at the base of the patient's neck to track the flow of blood in the aorta;
it presents the same data as the CardioQ-ODM in a similar format and is used for
taking snapshots or monitoring over short periods.



                      This information is provided by RNS
            The company news service from the London Stock Exchange